resisttb
- Jun 2, 2022
- 1 min read

WHO issues rapid communication on updated guidance for the treatment of drug-resistant tuberculosis

A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of drug-resistant tuberculosis (DR-TB). These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB. Read Here.

Recent Posts

See All

John Green & Grassroots Activists Pressure Danaher To Drop Price of Tuberculosis Test

“Why am I passionate about TB? It’s the deadliest disease in human history, but for most of human history we couldn’t do much about it. However, since the mid-1950s, TB has been curable — yet we still

Barely Contained Rage: An Open Letter to Danaher and Cepheid

"Danaher and Cepheid are using a printer-ink business model to overcharge for tuberculosis tests, thus resulting in millions of people going undiagnosed every year, many of whom will die." Watch the f

What’s new in the TB section of the 2023 WHO Model Lists of Essential Medicines

The World Health Organization’s (WHO’s) 2023 Model Lists of Essential Medicines, published in July 2023, features key updates to the tuberculosis (TB) section. These complement current WHO recommendat